Title 01: Race Oncology (ASX:RAC) lists on ASXCirca: 18 July...

Title 01: Race Oncology (ASX:RAC) lists on ASX
Circa: 18 July 2016
Description: Peter is interviewed about Race Oncology's recent listing on the ASX, their first asset ‘Bisantrene’ and their strategy to develop overlooked but clinically mature drugs.

Title 02: Race - logo update
Circa: 1 August 2016
Description: Founding CSO, Dr John Rothman, introduces himself and lists his previous endeavors in medical science. He goes into detail about the science behind Bisantrene, and how it was lost.



Title 03: What is Race Oncology?
Circa: 10 July 2017
Description: Peter gives an overview of Race Oncology and their recent collaboration with Targimmune.

Title 04: Race Oncology Bisantrene Production
Circa: 12 September 2017
Description: Peter visits IRISYS LLC in San Diego, California and presents the first GMP grade batch of Bisantrene Dihydrochloride produced by Race Oncology.



Title 05: Executive interview - Race Oncology
Circa: 9 October 2017
Description: Peter discusses Bisantrene's history and commercial prospects in treating AML. The goal of the Named Patient Program is explained.


Title 06: Race Oncology has a successful track record of profitably recycling old drugs
Circa: 14 November 2017
Description: Peter is interviewed at the Biotech and Money Conference at the Waldorf Hotel, London. He describes his background in relaunching products such as the Betadine throat gargle.



Title 07: Health Invest - Paul & Bill
Circa: 10 January 2018
Description: Dr Bill Garner is interviewed at the JP Morgan conference. He talks briefly about his involvement with Race Oncology, but mostly about his multiple other entrepreneurial pursuits. An interesting insight into his mindset.



Title 08: Dr John Cullity explains Race Oncology's unique business opportunity
Circa: 2 May 2018
Description: John gives his first interview after his appointment as non-executive director. He gives his background and how his skills and experience can benefit Race.



Title 09: Race Oncology director sees "extreme, untapped value" in company's cancer drug
Circa: 15 May 2018
Description: John gives an interview with Proactive Investors, giving an overview of Bisantrene and Race Oncology's clinical plans.



Title 10: Race Oncology (ASX:RAC) leukemia drug candidate update
Circa: 16 October 2018
Description: Peter discusses Bisantrene's commercial strategy, patent position, and Bisantrene's rare paediatric disease designation.



Title 11: Race Oncology AML Family
Circa: 20 February 2019
Description: Kara & Richard Nell share their tragic experience with 3 year old son Kai's battle with AML, and their hope for drugs like Bisantrene to make a difference for others.



Title 12: Race Oncology 2019 Annual General Meeting Presentation

Circa: 27 November 2019
Description: The 5 Path Strategy is presented to shareholders at the 2019 AGM. Peter discusses the challenges that they have faced in AML trials and the NPP. We are introduced to Dr Daniel Tillet, who speaks about his own journey from investor to director and explains the science behind the new direction for Race.



Title 13: Race Oncology presents at IRD Invest
Circa: 27 August 2020
Description: Daniel Tillet talks through the results of the 2020 AML trial in Israel. The City of Hope paper identifying Bisantrene as an inhibitor of FTO had been published 2 months earlier, and Daniel starts to explain the exciting opportunity that FTO presents.



Title 14: Race leadership team strengthened
Circa: 3 September 2020
Description: Interview with Phil and Daniel regarding Phil's appointment as CEO and their joint leadership of Race Oncology. John Cullity also gives his background and approach to Big Pharma M&A and Race's current position.



Title 15: Race Oncology's Daniel Tillett details positive preclinical results for Bisantrene in breast cancer
Circa: 24 November 2020
Description: Daniel is interviewed by Proactive Investors, giving details on the recent positive preclinical breast cancer results.



Title 16: Race Oncology AGM 2020
Circa: 30 November 2020
Description: The 3 Pillar Program and the pivot to pursue FTO is announced. Phil introduces the ‘New Race’ and gives an overview of management and the wider team of experts. Daniel dives into the science of FTO inhibition and how Race will pursue this new opportunity through Melanoma, ccRCC, and other programs.



Title 17: Bisantrene for R/R AML patients
Circa: 2 December 2020
Description: A short snippet of Prof Arnon Nagler presenting results from the R/R AML Bisantrene trial during the 62nd American Society of Hematology Annual Meeting and Exposition.



Title 18: ********* 'Hidden Gems' Webinar - Race Oncology ASX:RAC
Circa: 4 December 2020
Description: Daniel presents the 'New Race', highlighting the transformation from earlier in 2020. The 3 Pillar Program and FTO opportunity is explained.



Title 19: ASX CEO INTERVIEW : Race Oncology (ASX: RAC) – Daniel Tillett
Circa: 14 May 2021
Description: Daniel is interviewed on the ASX Investor channel. He discusses the history of Bisantrene and why he originally came on as an investor, then director. Race's plan to pursue the FTO opportunity and the 3 Pillar Program is explained.



Title 20: Race Oncology (ASX: RAC) Investor briefing - May 2021
Circa: 14 May 2021
Description: Phil and Daniel give an Investor Presentation, providing another an overview of the 3 Pillar Program, the new preclinicals in Melanoma, ccRCC, and heart safety - and the May cap raise with Bonus Options.



Title 21: UOW researchers closing in on CF breakthrough
Circa: 13 October 2017
Description: Prof Michael Kelso gives an interview discussing his work in drug formulation for Cystic Fibrosis. Kelso joined RAC as Principal Scientist in May 2021, working on new formulations of Bisantrene.



Title 22: An inquiry into FTO and Bisantrene: Race Oncology (ASX:RAC)

Circa: 20 May 2021
Description: Resident CSS (Chief Scientific Shareholder) @Mason14 gives a detailed breakdown of the science behind FTO, m6A RNA modifications, and how Bisantrene works to kill cancers.



Title 23: Race Oncology CSO, Daniel Tillett presents at *********'s Hidden Gems webinar
Circa: 11 June 2021
Description: Daniel goes through the science of FTO and the massive opportunity that Bisantrene has in this new space.



Title 24: A Speculative Peer M&A Comparison for Value: Race Oncology (ASX: RAC)
Circa: 15 June 2021
Description: In his 2nd video presentation on RAC, @Mason14 gives a speculative valuation of RAC and Zantrene as compared to acquisitions of other biotechs that focus on epitranscritomics.



Title 25: MST Access Australian Micro & Small Caps Conference 2021 - Race Oncology Limited
Circa: 17 June 2021
Description: Phil and Daniel present the new Race Oncology to institutional investors at MST Access conference.



Title 26: Race Oncology (ASX:RAC) CEO, Phillip Lynch presents at V-Con
Circa: 5 July 2021
Description: Phil presents the corporate structure of Race and the 3 Pillar Program. He touches on the new opportunity presented by FTO.



Title 27: Race Oncology (ASX: RAC) – The ASX Biotech With A Global Opportunity To Change Cancer Treatment
Circa: 25 July 2021
Description: Daniel is interviewed by the ASX investor channel. The 3 Pillar Strategy is explained, and Daniel details the preclinical programs that have been initiated. The scale of the FTO opportunity is discussed.



Title 28: Race Oncology (ASX: RAC) Day 2 of the IRD Invest 2021 conference
Circa: 29 September 2021
Description: Phil gives a presentation on past strategies for cancer treatment and how targeted therapies are the current standard. Daniel again goes through the FTO opportunity and RAC's announced preclinical programs.



Title 29: Race Oncology (ASX: RAC) reveals breakthrough chemotherapy heart protection discovery for Zantrene®
Circa: 22 November 2021
Description: Phil and Daniel announce the discovery of Zantrene's cardio-protective abilities. They discuss the enormous value of Zantrene being used alongside standard chemotherapy, rather than as a replacement.



Title 30: Race Oncology AGM 2021 CEO & CSO presentation with Share Purchase Program Investor Presentation
Circa: 24 November 2021
Description: The expanded 3 Pillar Program is introduced by Phil and Daniel. The new cardio-protective opportunity is explained in more detail. The SPP cap raise is discussed and the proposed expenditures are described.



Title 31: Investor Presentation
Circa: 24 November 2021
Description: Phil and Daniel give a more polished presentation of the programs discussed and announced earlier at the AGM.



Title 32: Race Oncology (ASX: RAC) – Breakthrough Cancer Treatment Discovery
Circa: 26 November 2021
Description: Daniel is interviewed again on the ASX Investor channel. He goes through the recent cardio-protection discovery and how this can be rapidly commercialized. The SPP and proposed expenditures are detailed. Daniel explains why he is so excited about Race Oncology.



Title 33: Race online Q+A investor briefing
Circa: 8 Dec 2021
Description: Phil, Daniel, and CMO David Fuller host a dedicated Q&A session for questions after the 2021 AGM regarding the Expanded 3 Pillar Program and the ongoing Share Purchase Plan.



Title 34: Race Oncology discuss Zantrene and what it means for the future
Circa: 14 December 2021
Description: Phil touches on FTO and how Race is pursuing that opportunity. The SPP is explained and how exactly that will fund the new expanded 3 Pillar Program. Phil discusses his time at J&J and how that influences his approach. Daniel details his path from investor to CSO and his take on the cardio-protection discovery.



Title 35: Race Oncology brings in $29.7 million war chest to "get to the clinic"
Circa: 21 December 2021
Description: Phil details the massive success of the oversubscribed SPP raise. He gives a brief explanation of Race's clinical strategy, and how the funds raised will be used.



Title 36: Race Oncology (ASX:RAC) raises $29.7m in an oversubscribed SPP
Circa: 21 December 2021
Description: Daniel discusses the outcome of the oversubscribed SPP, how the scale back was allocated, and how the funds will be used. The FTO and Cardio-protective opportunities are detailed.


Title 37: Race Oncology raises $29.7m to fund development of lead anti-cancer drug Zantrene
Circa: 22 December 2021
Description: Daniel is interviewed by Small Caps, going into detail about the history of Race Oncology, the FTO opportunity, the Cardio-Protective opportunity, and the successful SPP. The marketing strategy to Big Pharma is discussed.